The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
Compounds
申请人:Incanthera Ltd.
公开号:US20150196658A1
公开(公告)日:2015-07-16
The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.
COMPOUNDS CONTAINING A VASCULAR DISRUPTING AGENT
申请人:Incanthera Ltd
公开号:US20160243252A1
公开(公告)日:2016-08-25
The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.